Tags

Type your tag names separated by a space and hit enter

Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease.
Acta Neurol Scand 2017; 135(2):252-256AN

Abstract

BACKGROUND

Ethnic diversity between different populations may affect treatment safety and efficacy.

AIMS AND METHODS

A subanalysis to a global trial (study 326) was carried out to ascertain the safety and efficacy of donepezil 23 mg/day compared with donepezil 10 mg/day in Asian patients with moderate-to-severe Alzheimer's disease. Changes in cognition and global functioning were measured by the Severe Impairment Battery (SIB) and Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus), respectively, at week 24.

RESULTS

Cognitive improvement measured by SIB score was greater with donepezil 23 mg than with donepezil 10 mg (+1.36 vs -1.56]; difference, 2.92). There was no difference between the groups in global function measured by the CIBIC-Plus (3.94 and 3.95, respectively). Overall, 119 patients (82.1%) receiving donepezil 23 mg and 56 (71.8%) receiving donepezil 10 mg experienced ≥1 treatment emergent adverse events (TEAEs). In the donepezil 23 mg group, the incidence of TEAEs was higher among patients of lower weight (<55 kg) at baseline than in those of higher weight (64 of 75 patients [85.3%] vs 55 of 70 patients [78.5%]).

CONCLUSIONS

The benefits and risks associated with donepezil 23 mg in Asian patients are comparable to those of the global study population.

Authors+Show Affiliations

Department of Neurology, Konkuk University Hospital, Seoul, South Korea.Department of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.Department of Neurology, Clinical Neuroscience Center & Neurology, Seoul National University Bundang Hospita, Gyeonggi-do, South Korea.Department of Neurology, Dong-A University College of Medicine, Dong-A University Hospital, Busan, South Korea.Department of Pharmacology, National University of Singapore and Memory Aging and Cognition Center, National University Health System, Singapore, Singapore.Department of Neurology, Neuroscience Centre, AIIMS, New Delhi, India.Regional Medical Advisor, Eisai Pharmaceuticals India Pvt. Ltd., Mumbai, India.Clinical Development Eisai Co. Ltd., Tokyo, Japan.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

26923256

Citation

Han, S-H, et al. "Donepezil 23 Mg in Asian Patients With Moderate-to-severe Alzheimer's Disease." Acta Neurologica Scandinavica, vol. 135, no. 2, 2017, pp. 252-256.
Han SH, Lee JH, Kim SY, et al. Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease. Acta Neurol Scand. 2017;135(2):252-256.
Han, S. H., Lee, J. H., Kim, S. Y., Park, K. W., Chen, C., Tripathi, M., ... Kubota, N. (2017). Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease. Acta Neurologica Scandinavica, 135(2), pp. 252-256. doi:10.1111/ane.12571.
Han SH, et al. Donepezil 23 Mg in Asian Patients With Moderate-to-severe Alzheimer's Disease. Acta Neurol Scand. 2017;135(2):252-256. PubMed PMID: 26923256.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease. AU - Han,S-H, AU - Lee,J-H, AU - Kim,S Y, AU - Park,K W, AU - Chen,C, AU - Tripathi,M, AU - Dash,A, AU - Kubota,N, Y1 - 2016/02/29/ PY - 2016/01/28/accepted PY - 2016/3/1/pubmed PY - 2017/3/3/medline PY - 2016/3/1/entrez KW - Asia KW - alzheimer disease KW - cognition KW - donepezil SP - 252 EP - 256 JF - Acta neurologica Scandinavica JO - Acta Neurol. Scand. VL - 135 IS - 2 N2 - BACKGROUND: Ethnic diversity between different populations may affect treatment safety and efficacy. AIMS AND METHODS: A subanalysis to a global trial (study 326) was carried out to ascertain the safety and efficacy of donepezil 23 mg/day compared with donepezil 10 mg/day in Asian patients with moderate-to-severe Alzheimer's disease. Changes in cognition and global functioning were measured by the Severe Impairment Battery (SIB) and Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus), respectively, at week 24. RESULTS: Cognitive improvement measured by SIB score was greater with donepezil 23 mg than with donepezil 10 mg (+1.36 vs -1.56]; difference, 2.92). There was no difference between the groups in global function measured by the CIBIC-Plus (3.94 and 3.95, respectively). Overall, 119 patients (82.1%) receiving donepezil 23 mg and 56 (71.8%) receiving donepezil 10 mg experienced ≥1 treatment emergent adverse events (TEAEs). In the donepezil 23 mg group, the incidence of TEAEs was higher among patients of lower weight (<55 kg) at baseline than in those of higher weight (64 of 75 patients [85.3%] vs 55 of 70 patients [78.5%]). CONCLUSIONS: The benefits and risks associated with donepezil 23 mg in Asian patients are comparable to those of the global study population. SN - 1600-0404 UR - https://www.unboundmedicine.com/medline/citation/26923256/Donepezil_23_mg_in_Asian_patients_with_moderate_to_severe_Alzheimer's_disease_ L2 - https://doi.org/10.1111/ane.12571 DB - PRIME DP - Unbound Medicine ER -